Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00877656 | HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma | PHASE2 | COMPLETED | 21 | — | — | Aug 1, 2005 | Dec 1, 2008 | Mar 18, 2024 | - | — |
| Arm | Type | Description |
|---|---|---|
| CD4 | EXPERIMENTAL | Open label treatment arm |
| Name | Type | Description |
|---|---|---|
| HuMax-CD4 | BIOLOGICAL | Active treatment |
Inclusion Criteria: * Diagnostic biopsy of non cutaneous T Cell lymphoma with positive phenotype * Relapsed or refractory to minimum of one course of chemotherapy * Study is closed to enrollment.
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Soligenix, Inc. | SNGX | 1 | PHASE3 | Hypericin |
| Incyte Corporation | INCY | 2 | PHASE2 | Ruxolitinib, Pembrolizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | — | Undisclosed |